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Abstract: 
Niosomes are efficient carriers for controlled drug delivery, to entrap hydrophilic drugs in the larger interior 
aqueous layer, whereas, lipophilic drugs in the outer lipid bilayers. Since, the niosomes are biodegradable and 
non toxic and hence, a good carrier for targeting of therapeutic agents at the site of interest with reduced 
systemic toxicity. The film formation method was used for the preparation of the niosomes due to simplicity, 
reproducibility and high drug entrapment efficiency. The various ratios of Surfactant (Span 60) Cholesterol and 
Dicetyl phosphate (DCP) were used for the preparation of the niosomes. The molar ratio of 47.5:47.5:5 was 
found to be most suitable in terms of niosomal size drug entrapment efficiency and in vitro drug release. The 
average size of niosomes was observed as 4.5 µ m with drug entrapment efficiency of 62.4%. The in vitro drug 
release study was carried out using dialysis membrane in Phosphate buffer saline (PBS, pH 7.4) for 24 hrs.  The 
result showed a cumulative drug release of 98% in 8 hrs. from the free drug, against 92% drug release in 24 hrs. 
With optimized niosomal formulation. The optimized niosomal formulation showed a sustained action of about 
16 hrs was subjected to in vivo studies (anti-inflammatory activity). This formulation was found to be more 
effective in reducing edema after 2 hrs as compared to the free drug. 
Key-word: - Niosomes, biodegradable, film formation method, drug entrapment efficiency, dialysis membrane. 
1) Introduction:-  
Target oriented drug delivery systems are the areas of the major interest in the modern pharmaceutical research. 
The selective drug delivery to the target tissues increases the therapeutic efficacy of the drug and reduces its 
undesirable effect to non target tissues. The concept of drug targeting or site specific drug delivery was 
introduced first time by Paul Elrich in 1909, when he reported ‘magic bullet’ to deliver a drug to the desired site 
of action without affecting the non target organs or tissues (Juliano, 1980) by associating the drug with a 
pharmacologically “inactive carrier” capable of conveying the drug selectively towards its target cells. 
Niosomes are efficient carriers for controlled drug delivery, to entrap hydrophilic drugs in the larger interior 
aqueous layer, whereas, lipophilic drugs in the outer lipid bilayers. Since, the niosomes are biodegradable and 
non toxic and hence, a good carrier for targeting of therapeutic agents at the site of interest with reduced 
systemic toxicity. Ketoprofen, non-steroidal anti-inflammatory drug, is used for the treatment of rheumatoid 
arthritis, osteoarthritis, degenerative joint conditions and musculoskeletal disorders, involving long term 
therapy. Ketoprofen has various side effects like gastritis, peptic ulcer and bleeding, along with short biological 
half life (0.5-2 hrs) which calls for frequent administration. Thus, a novel and controlled drug delivery system 
need to be developed in order to increase its therapeutic effects with reduced side effects. The result obtained in 
our findings reveals that vesicular niosomes may be very useful as a sustained release delivery system of 
ketoprofen as compared to the free drug. 
2) Materials & Method:-  
               It is given in table 1 & 2. 
 
2.1) Method:- 
2.1.1) Preparation of different batches of Niosomes:-  
Advances in Life Science and Technology  www.iiste.org 
ISSN 2224-7181 (Paper) ISSN 2225-062X (Online) 
Vol 3, 2012 
2 
A different batch of Niosomes was prepared using experimental conditions include: 
Surfactant Concentration   : 100 µmol 
Rotation Time    :  2 h 
Hydration Time   : 1 h 
Temperature of water bath                : 50º C 
The entire process of preparation of niosomes has been shown in the flow diagram in fig. 1. 
2.1.2) Optimization of formulation:-  
                      Formulation shall be optomized on the basis of -  
2.1.2.1) rotation speed of rotary evaporator.  
2.1.2.2) surfactant concentration.  
2.1.2.3) composition of bilayers etc. 
                               2.1.2.1)  Rotation speed of rotary evaporator. 
In order to investigate the effect of rotational speed on niosomal formulations, the niosomes 
were prepared at three different rotations i. e. 60, 80 and 100 r.p.m., at the  100 r.p.m. the 
maximum number of niosomes possessed an average size of 4.5 µm. 
The uniformity was more at 100 r.p.m. hence; the effect of rotational speed of vacuum 
evaporator on size distribution of niosomes was investigated at 100 rpm. 
Explain in table no. 3 & fig 2. 
2.1.2.2) Surfactant concentration.  
The niosome were prepared with concentration of surfactant and found that mixture of 
surfactant, cholesterol and dicetyl phosphate (in a molar ratio of 47.5: 47.5: 5) were best 
due-to the average size 4.5 µm of niosome were formed.Explain in table no. 4 & fig 3. 
2.1.2.3) composition of bilayers –  
Among the various formulations, the most appropriate ratio of cholesterol: surfactant: DCP 
was identified as 47.5: 47.5: 5 as it produced stable niosome with maximum entrapment 
efficiency.Explain in table no. 5. 
 
 
 
3) Evaluation of formulation:-  
3.1) Microscopic study of niosomal Size -  
           niosomes were subjected to particle size analysis using optical microscope by standardizing the eye piece 
micrometer scale with stage micrometer scale. 
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3.2) Morphology – 
             The niosomal suspensions were evaluated for morphological characteristics using transmission electron 
microscopy (TEM). Explain in fig no 4, 5 & 6. 
3.3) Determination of drug entrapment efficiency –  
                                   The percent entrapment was calculated using the following formula  ( Huang, C.H., 1969). 
Explain in fig no.13. 
                                                      % Entrapment = 
100
(mg) addeddrug Total 
(mg)drug  Entrapped
×  
3.4) In Vivo & In vitro Study of formulation 
3.4.1) The in vivo anti-inflammatory studies is carried out by        
             carrageenan induced rat hind paw oedema method. Explain in table no 6. 
3.4.2) In-vitro Study is carry out by using dialysis membrane. Explain in table no 7 & fig no.7. 
4)  Stability study of Formulation as per ICH Guideline. 
 Explain in detail in the given data of table & fig. which is given below. 
5) Results and Discussion 
Among the reported methods for the preparation of niosomes, lipid film hydration technique was used due to its 
simplicity and reproducibility as compared to others. The formulation variables were optimized with regard to 
rotations per minute, surfactant concentration, composition and Span 60: Cholesterol: DCP ratio. They were 
characterized with respect to drug entrapment efficiency, particle size analysis, morphological characteristics 
and in vitro drug release study.The drug entrapment efficiency of various formulations was compared. Based on 
the data, it was found that niosomes prepared with Span 60: Cholesterol: DCP (47.5: 47.5: 5) gave maximum 
drug entrapment. Hence, the niosomes were prepared using the above said composition. The photomicrography 
of the niosomes revealed spherical shape and multilamellar structure of niosomes.The particle size analysis of 
niosomes using optical microscopy revealed niosomes with a mean diameter of 4.5 µm. The In vitro drug 
release studies of different batches of niosomal encapsulated formulations using pure Surfactant, Surfactant and 
Cholesterol, and Surfactant, Cholesterol: DCP (47.5 : 47.5 : 5) were carried out using dialysis membrane. These 
studies were carried out in a self designed diffusion cell over a period of 24 hrs in phosphate buffer saline 
(PBS). The rate of release of ketoprofen across dialysis membrane from loaded vesicles was slower than that of 
free ketoprofen solution as a control. The results showed that approximately 98% of drug was released within 8 
h from control solution, whereas the release of ketoprofen from the Span 60, Span 60: Cholesterol and Span 60: 
Cholesterol: DCP was 97, 95 and 92.53 per cent respectively in 24 h. Of these Span 60: Chol: DCP yields 
slowest rate of release. The release occurred in two phases, an initial burst release lasting for 2 to 7 h followed 
by sustained but reduced release for 24 h. The biphasic release pattern might be due to size heterogeneity of the 
vesicles. The comparative release data indicate that, by niosome encapsulation, it is possible to sustain and 
control the release of drug for a longer duration. 
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Table 1:- List of Drug/chemicals:- 
Sr. 
No. 
Materials/Chemicals Manufacturer 
1. Ketoprofen Hindustan Biosciences Ltd., Hyderabad 
2. Cholesterol Loba Chemie Pvt. Ltd., Mumbai 
3. Dicetyl phosphate Sigma Aldrich, USA 
4. Span 60 (Sorbitan monosterate S.d. Fine Chem Ltd., Mumbai 
5. Disodium hydrogen phosphate Qualigen Fine Chemicals, Mumbai 
6. Potassium dihydrogen phosphate Qualigen Fine Chemicals, Mumbai 
7. Sodium chloride (AR Grade) Qualigen Fine Chemicals, Mumbai 
8. Diethyl ether Central Drug House (P) Ltd., New Delhi 
9. Methanol (AR Grade) Qualigen Fine Chemicals, Mumbai 
10. Chloroform Spectrochem Pvt. Ltd., Mumbai 
11. Triton X 100 L.R. S.d. Fine Chem. Ltd., Mumbai 
12. Sephadex G-50 Sigma Aldrich, USA 
13. Acetone Qualigen Fine Chemicals, Mumbai 
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14. Sodium acetate S.d. Fine Chem. Ltd., Mumbai 
15. Dialysis tubing Sigma Aldrich, USA 
 
Table 2:- List of Equipments:- 
Sr. 
No. 
Equipment Manufacturer 
1. UV-Visible Spectrophotometer Perkin Elmer EZ 301 Double beam 
2. Digital pH meter Systronics 
3. Electronic Balance A & D Japan 
4. Rotary vacuum evaporator Steroglass, Italy 
5. Microscope Olympus (India) Pvt. Ltd., Delhi 
6. Vacuum Pump Ital Scientific, Genova 
7. Magnetic Stirrer with hot plate Remi Sales & Engg. Ltd., Mumbai 
8. Research Centrifuge Remi Sales & Engg. Ltd., Mumbai 
9. Digital Vernier Caliper Mitutoyo digimatic, Japan 
10. Transmission electron microscope Fei-Philips Morgagni 268 D 
11. Water Bath Narang Scientific Works Pvt. Ltd., Delhi 
12. Diffusion Cell Fabricated 
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The entire process of preparation of niosomes has been shown in the flow diagram. 
Surfactant: Cholesterol: DCP in 20 ml diethyl ether in a round bottom flask (Quick fit neck B-24 joint) 
 
Rotary vacuum evaporator at 100 rpm 
 
Formation of dry lipid film 
 
Hydration of the film with 10 ml PBS for 1 hour at 600C with gentle shaking 
 
Separation of hydrated niosomes from the free drug by Sephadex G-50 mini column method. 
 
Purified niosomes 
 
Storage of purified niosomes in vials (in refrigerator) till further use 
Fig 1: Flow diagram showing preparation of niosomes of ketoprofen 
Table 3: The effect of rotational speed of rotary vacuum evaporator on the size distribution of niosomes 
Rotational 
Speed 
(rpm) 
Size Range 
(µm) Mean size (µm) 
Average number of 
Niosomes (n = 3) 
100 
0-3 1.5 13.66 ± 1.24 
3-6 4.5 40.00 ± 3.29 
6-9 7.5 23.66 ± 2.05 
9-12 10.5 16.33 ± 0.82 
12-15 13.5 5.66 ± 0.12 
15-18 16.5 1.33 ± 0.00 
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Fig. 2: Size distribution of niosomes prepared at 100 r.p.m. 
Table 4: the effect of variable ratio of surfactant, cholesterol on size distribution of Niosomes. 
Ratio of 
Surfactant : 
Cholesterol : 
DCP 
Size Range 
(µm) 
Mean size 
(µm) 
Average number of Niosomes 
(Mean ± SD) 
(n = 3) 
47.5 : 47.5 : 5 
0-3 1.5 36.33 ± 2.94 
3-6 4.5 51.33 ± 4.32 
6-9 7.5 8.66 ± 1.70 
9-12 10.5 3.00 ± 00 
12-15 13.5 1.66 ± 0.33 
15-18 16.5 1.0 ± 00 
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Fig. 3: Size distribution of niosomes prepared with a mixture of surfactant, cholesterol and DCP (47.5 : 47.5 : 5) 
Table 5: Effect of varying composition of surfactant, cholesterol and DCP on Entrapment Efficiency 
Composition of Bilayer Percent Entrapment 
B1 Pure surfactant (100 µ mol) 52.19 ± 0.79 
B2 Surfactant : Cholesterol : : 50 : 50 61.84 ± 1.26 
B3 Surfactant : Cholesterol : DCP (47.5 : 47.5 : 5) 62.45 ± 0.34 
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Fig. 4:- Niosomes prepared using surfactant (100 µ mol) 
 
Fig 5:- Niosomes prepared using surfactant : cholesterol : : 50 : 50 
 
                       Fig 6:- Niosomes prepared using surfactant: cholesterol: DCP (47.5: 47.5: 5) 
Table 6: Effect of Free and Niosomes Encapsulated Ketoprofen on Development of Oedema after Intra-planter 
Injection of Carrageenan 
Treatment 
 
% Inhibition of Paw Oedema * 
(Mean ± SD), n = 6 
1h 2h 3h 4h 5h 
Free Ketoprofen 
0.3 mg/kg 
50.22 ±2.59 38.46 ±3.58 30.12 ± 2.74 22.25 ±3.24 10.38 ±1.86
 
Free Ketoprofen 3mg/kg 72.48 ±1.42 a 66.32 ±2.56 a 48.12 ± 0.34 a 38.34 ±1.26 a 20.24 ±1.26 a 
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Niosomal Ketoprofen 0.3mg/kg 50.34 ±2.16 48.21 ±1.24 a 45.21 ± 2.34 a 42.34 ±0.24 a 36.42 ±0.88 a 
a Significant difference as compared to free Ketoprofen (0.3 mg/kg) treatment, 
Table 7: In vitro release data of ketoprofen from niosomal and non niosomal formulation 
Time (hr) Control Span 60 S:C S:C:D 
0 0 0 0 0 
1 12.32 5.36 3.64 2.25 
2 25.32 15.38 8.97 6.74 
3 49.53 19.85 14.25 10.56 
4 55.36 25.38 22.86 15.79 
5 69.23 34.66 35.96 22.35 
6 82.39 46.33 45.26 35.84 
7 89.45 58.27 58.27 48.28 
8 98.36 71.85 65.98 56.98 
12  85.96 79.64 72.24 
16  93.87 88.35 82.3 
24  97.64 95.46 92.53 
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Fig. 7: Cumulative release profile of ketoprofen from niosomal formulation 
Table 8: Effect of temperature on drug retention of niosomes using Surfactant : Cholesterol : DCP (47.5 : 47.5 : 
5) 
Time 
Drug Entrapment (%) 
4-7 °C 30 ± 2 °C 40-45 °C 
1st week 60.48 ± 0.96 58.92 ± 0.34 54.32 ± 0.74 
2nd week 56.34 ± 1.24 55.44 ± 0.53 49.24 ± 0.86 
3rd week 54.86 ± 0.22 53.27 ± 1.24 47.38 ± 0.98 
4th week 52.24 ± 0.86 50.12 ± 1.36 42.21 ± 0.12 
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Table 9: Aggregation and disruption behaviour of ketoprofen niosomes at various temperatures. 
Time 
4-7 °C 
Room Temperature 
30 ± 2 °C 
40-45 °C 
Aggregation Disruption Aggregation Disruption Aggregation Disruption 
1st week + - + - + - 
2nd week ++ - + 1 + 1 
3rd week +++ - + 2 - 2 
4th week +++ 1 ++ 2 - 2 
Degree of aggregation:  Degree of disruption (out of 100 vesicles): 
+ 5-10%;    1— 0-5; 
++ 10-20%;   2— 5-10; 
+++ 20-30%;   3— 10-15; 
++++ 30-40%   4— 15-20 
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Figure 8: Effect of temperature on drug leakage from niosomal vesicles 
0
20
40
60
80
100
0 4 8 12 16 20 24
%
Cu
m
u
la
tiv
e 
re
le
as
e
Time(hrs)
4-7 C
RT
 
 
Figure 9: Cumulative release profile of ketoprofen from niosomal formulation after 1st week 
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Figure 10: Cumulative release profile of ketoprofen from niosomal formulation after 2nd week 
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Figure 11: Cumulative release profile of ketoprofen from niosomal formulation after 3rd week 
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Figure 12: Cumulative release profile of ketoprofen from niosomal formulation after 4th week 
Composition of Bilayer Percent Entrapment 
Surfactant : Cholesterol : DCP (47.5 : 47.5 : 5) 62.45 ± 0.34 
 
Fig 13. Composition of bilayers. 
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